The Patent Finder

Cephalon Australia Pty Ltd.

Also on record
Records under this name other than patents Cephalon Australia Pty Ltd. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.

Back to Cephalon Australia Pty Ltd.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
US 9,505,826Modified antibody with improved half-life
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 9,963,515Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
Formerly held
In force
 · USPTO record
In forceUSPTO record
US 8,563,697Anti-IL-12/IL-23 antibodies
Formerly held
Lapsed on the fee record
Ended Oct 22, 2021 · USPTO record
Lapsed on the fee recordEnded Oct 22, 2021USPTO record
US 8,343,490Monoclonal antibody SC104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
Formerly held
Lapsed on the fee record
Ended Jan 1, 2021 · USPTO record
Lapsed on the fee recordEnded Jan 1, 2021USPTO record
US 8,273,349Binding member which binds to both lewis-Y and lewis-B haptens, and its use for treating cancer
Formerly held
Lapsed on the fee record
Ended Sep 25, 2020 · USPTO record
Lapsed on the fee recordEnded Sep 25, 2020USPTO record
US 7,267,821Binding member which binds to both Lewisy and Lewisb haptens, and its use for treating cancer
Formerly held
Lapsed on the fee record
Ended Sep 11, 2019 · USPTO record
Lapsed on the fee recordEnded Sep 11, 2019USPTO record
US 9,127,057Anti-IL-23 heterodimer specific antibodies
Formerly held
Lapsed on the fee record
Ended Sep 8, 2019 · USPTO record
Lapsed on the fee recordEnded Sep 8, 2019USPTO record
US 7,915,387Monoclonal antibody Sc104 and derivative thereof specifically binding to a sialyltetraosyl carbohydrate as a potential anti-tumor therapeutic agent
Formerly held
Lapsed on the fee record
Ended Mar 29, 2019 · USPTO record
Lapsed on the fee recordEnded Mar 29, 2019USPTO record
US 7,879,983Binding member which binds to both Lewis-y and Lewis-b haptens, and its use for treating cancer
Formerly held
Lapsed on the fee record
Ended Feb 1, 2019 · USPTO record
Lapsed on the fee recordEnded Feb 1, 2019USPTO record
US 8,932,588Treatment of cancer involving mutated KRAS or BRAF genes
Formerly held
Lapsed on the fee record
Ended Jan 13, 2019 · USPTO record
Lapsed on the fee recordEnded Jan 13, 2019USPTO record
10 of 25 patents shown.
Pro members see all 25.
Pro members: see all 25 patents
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited